胸段食管鳞癌诱导化疗联合同期放化疗对比同期放化疗的配对分析

doi:10.3760/cma.j.issn.1004-4221.2019.02.003

Abstract
Figure/Table
References()
Related Citation (15)
Read Tracking
Download Tracking

Download: PDF (0 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS) Supporting Info

Abstract Objective To compare the clinical efficacy and safety between induction chemotherapy (IC) followed by concurrent chemotherapy (CRT) and CRT alone in patients with inoperable thoracic esophageal squamous cell carcinoma (ESCC). Methods Between 2002 and 2015, clinical data of 267 thoracic ESCC patients undergoing definitive CRT based on docetaxel combined with cisplatin were retrospectively analyzed. Through a matched case-control study, 85 patients receiving IC combined with CRT were matched to those undergoing CRT alone at a ratio of 1vs.1, according to age, gender, performance status, tumor location, tumor length, and TNM staging as the matching factors. Clinical efficacy and safety between two groups were statistically compared. Kaplan-Meier survival analysis was used to analyze the survival. The log-rank test was adopted to examine within-group differences. The Cox regression model was used for multivariate analysis. Results The median follow-up time for 170 patients was 18 months (range, 3-72 months). The overall objective response rates in the IC and CRT groups were 74.1% and 58.8%(P=0.035). The 3-year overall survival (OS) and progress-free survival (PFS) rates in the IC group were 44.2% and 34.8%, significantly higher than 29.7% and 15.4% in the CRT group (P=0.028, P=0.015). Subgroup analysis revealed that patients responsive to IC obtained significantly better OS (P=0.002), PFS (P=0.001), and local recurrence-free survival (LRFS)(P=0.002) compared with the IC non-responder, whereas the distant metastasis-free survival (DMFS) did not significantly differ (P=0.166). The incidence rate of grade 3–4 leukopenia in the IC group was significantly higher than that in the CRT group (38.8% vs. 24.7%, P=0.048). Multivariate analysis revealed that age and the addition of IC were independent prognostic factors for OS (P=0.003,0.016). Conclusions Compared with concurrent CRT, IC in combination with CRT can yield better short-term efficacy and longer survival for ESCC patients. The risk of hematological toxicity in the IC group is relatively higher but tolerable. Prospective randomized trials are required to confirm the clinical efficacy and safety of IC for thoracic ESCC patients.

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	Wang Xiushen
	Xi Mian
	Bu Shanshan
	Xu Gang
	Ge Hong

Key words： Esophageal neoplasms/concurrent chemoradiotherapy Induction chemotherapy Prognosis

Received: 09 October 2018

Cite this article:

Wang Xiushen,Xi Mian,Bu Shanshan et al. Comparative analysis between induction chemotherapy combined with concurrent chemoradiotherapy and chemoradiotherapy alone for thoracic esophageal squamous cell carcinoma[J]. Chinese Journal of Radiation Oncology, 2019, 28(2): 90-95.

URL:

http://journal12.magtechjournal.com/Jweb_fszlx/EN/10.3760/cma.j.issn.1004-4221.2019.02.003 OR http://journal12.magtechjournal.com/Jweb_fszlx/EN/Y2019/V28/I2/90

[1] Chen W,Zheng R,Baade PD,et al. Cancer statistics in China,2015[J].CA Cancer J Clin,2016,66(2):115-132.DOI:10.3322/caac.21338.
[2] Rustgi AK,El-Serag HB.Esophageal carcinoma[J].N Engl J Med,2014,371(26):2499-2509.DOI:10.1056/NEJMra1314530.
[3] Cooper JS,Guo MD,Herskovic A,et al. Chemoradiotherapy of locally advanced esophageal carcinoma:long-term follow-up of a prospective randomized trial (RTOG 85-01)[J].JAMA,1999,281(17):1623-1627.
[4] Conroy T,Galais MP,Raoul JL,et al. Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/ACCORD17):final results of a randomised,phase 2/3 trial[J].Lancet Oncol,2014,15(3):305-314.DOI:10.1016/S1470-2045(14)70028-2.
[5] Sudo K,Xiao L,Wadhwa R,et al. Importance of surveillance and success of salvage strategies after definitive chemoradiation in patients with esophageal cancer[J].J Clin Oncol,2014,32(30):3400-3405.DOI:10.1200/JCO.2014.56.7156.
[6] Sun Y,Li WF,Chen NY,et al. Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma:a phase 3,multicentre,randomised controlled trial[J].Lancet Oncol,2016,17(11):1509-1520.DOI:10.1016/S1470-2045(16)30410-7.
[7] Monjazeb AM,Riedlinger G,Aklilu M,et al. Outcomes of patients with esophageal cancer staged with fluorodeoxyglucose positron emission tomography (FDG-PET):can postchemoradiotherapy FDG-PET predict the utility of resection?[J].J Clin Oncol,2010,28(31):4714-4721.DOI:10.1200/JCO.2010.30.7702.
[8] Stahl M,Stuschke M,Lehmann N,et al. Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus[J].J Clin Oncol,2005,23(10):2310-2317.DOI:10.1200/JCO.2005.00.034.
[9] Ajani JA,Xiao L,Roth JA,et al. A phase Ⅱ randomized trial of induction chemotherapy versus no induction chemotherapy followed by preoperative chemoradiation in patients with esophageal cancer[J].Ann Oncol,2013,24(11):2844-2849.DOI:10.1093/annonc/mDT339.
[10] Yoon DH,Jang G,Kim JH,et al. Randomized phase 2 trial of S1 and oxaliplatin-based chemoradiotherapy with or without induction chemotherapy for esophageal cancer[J].Int J Radiat Oncol Biol Phys,2015,91(3):489-496.DOI:10.1016/j.ijrobp.2014.11.019.
[11] Minsky BD,Neuberg D,Kelsen DP,et al. Final report of Intergroup Trial 0122(ECOG PE-289,RTOG 90-12):Phase Ⅱ trial of neoadjuvant chemotherapy plus concurrent chemotherapy and high-dose radiation for squamous cell carcinoma of the esophagus[J].Int J Radiat Oncol Biol Phys,1999,43(3):517-523.
[12] Michel P,Adenis A,Di Fiore F,et al. Induction cisplatin-irinotecan followed by concurrent cisplatin-irinotecan and radiotherapy without surgery in oesophageal cancer:multicenter phase Ⅱ FFCD trial[J].Br J Cancer,2006,95(6):705-709.DOI:10.1038/sj.bjc.6603328.
[13] Xi M,Liao Z,Deng W,et al. Recursive Partitioning analysis identifies pretreatment risk groups for the utility of induction chemotherapy before definitive chemoradiation therapy in esophageal cancer[J].Int J Radiat Oncol Biol Phys,2017,99(2):407-416.DOI:10.1016/j.ijrobp.2017.05.050.
[14] Stahl M,Stuschke M,Lehmann N,et al. Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus[J].J Clin Oncol,2005,23(10):2310-2317.DOI:10.1200/JCO.2005.00.034.
[15] Akinori M,Michitaka H,Yousuke T,et al. Induction chemotherapy followed by chemoradiotherapy for T4M0 esophageal cancer[J].Esophagus,2011,8(1):31-37.
[16] zum Büschenfelde CM,Herrmann K,Schuster T,et al.(18) F-FDG PET-guided salvage neoadjuvant radiochemotherapy of adenocarcinoma of the esophagogastric junction:the MUNICON Ⅱ trial[J].J Nucl Med,2011,52(8):1189-1196.DOI:10.2967/jnumed.110.085803.
[17] Ku GY,Kriplani A,Janjigian YY,et al. Change in chemotherapy during concurrent radiation followed by surgery after a suboptimal positron emission tomography response to induction chemotherapy improves outcomes for locally advanced esophageal adenocarcinoma[J].Cancer,2016,122(13):2083-2090.DOI:10.1002/cncr.30028.